Pancreatic Cancer Alliance

06/03/2026

"The results presented at the American Society of Clinical Oncology (ASCO) Annual Meeting for Revolution Medicine’s drug daraxonrasib represent the most significant advance we have ever seen in . For a disease that has long been marked by limited treatment options and often devastating outcomes, seeing a therapy double overall survival in previously treated metastatic pancreatic cancer patients is very encouraging. AND we are told that we will be getting it at UMass Memorial CanUMass Memorial Medical Centery soon. 💜🤞🙏

https://dailynews.ascopubs.org/do/rasolute-302-new-treatment-paradigm-metastatic-pdac-oncogenic-ras-targeting

05/15/2026

Record breaking funding of $25 million this year! $10 million more than ever before! Thank you Pancreatic Cancer Action Network

05/14/2026

We are pleased to acknowledge the exceptional work of Chaitanya Naimesh Parikh, our Pancreatic Cancer Alliance Fellow, for his diligence and commitment.

————————————————————————
Morningside Graduate School of Biomedical Sciences Cancer Biology Program
Announces the PhD Dissertation Defense of

CHAITANYA NAIMESH PARIKH

Development of Multiplexed Cytokine and Antigen mRNA Therapy for Immune-Mediated Tumor Control in Pancreatic Cancer
————————————————————————

04/16/2026

The Hope garden is planted!
Thank you to everyone who purchased pansies 🙏

04/14/2026

THIS!!

A new therapy that targets RAS mutations present in more than 90% of patients with pancreatic adenocarcinoma — the most common type of pancreatic cancer — approximately doubles overall survival according to clinical trial results announced today. 🧪

Revolution Medicines shared Phase III clinical trial results for a pill called daraxonrasib in patients with previously treated metastatic . For decades, RAS was considered “undruggable,” meaning that there was no effective way to target RAS. These results greatly expand the potential benefit of targeted therapies for patients with pancreatic cancer.

PanCAN Chief Scientific and Medical Officer Anna Berkenblit, MD, MMSc, shares, “We are standing at the threshold of groundbreaking treatments for patients with pancreatic cancer. Today’s announcement represents a real opportunity to bring new hope for people facing this disease: hope for more time with family, hope for better quality of life and hope that ongoing and future research may ultimately lead to a cure.” 💜

Next, Revolution Medicines will need to take their data to the U.S. Food and Drug Administration (FDA). If the FDA grants approval for daraxonrasib, it will be made available as a treatment for patients with metastatic pancreatic adenocarcinoma who have been previously treated.

For what you need to know about this news, visit 🔗 http://pcan.at/rjul9sza.

04/10/2026

WHAT A WEEK!
Finally some nice weather to deliver smiles
Hope everyone who wanted them got their order in. We will be delivering all weekend!

03/22/2026

ITS NOT TOO COLD FOR OUR LOCALLY GROWN PANSIES.
Pansies are cool-season annuals that thrive in temperatures between 45 and 65 degrees
making them ideal for spring and fall climates. They are frost-hardy, surviving temperatures down to 25 degrees but struggle when temps get to 75

03/19/2026

11/22/2025

At our symposium on Thursday, William Freed Pastor, MD, Ph.D spoke about new research from Dana-Farber’s Hale Family Center for Pancreatic Cancer Research and how they’re paving the way toward earlier detection and more effective treatments for pancreatic cancer.
By using AI to spot early warning signs, developing groundbreaking RAS-targeted therapies and novel immunotherapies, we are entering “an amazing new era” in pancreatic cancer care.

11/21/2025

World Pancreatic Cancer Day at The Kenneth F. Burns Memorial Bridge in the Town of Shrewsbury, Massachusetts.